EPO and retinopathy of prematurity: This study found that in preterm infants with a body weight lower than 1000 g receiving erythropoietin therapy, the occurrence of ROP was double than that of preterm infants that did not receive erythropoietin, suggesting this therapy as an independent risk factor for ROP development.